'Govt allowing this to happen': Supreme Court questions overpricing of medicines, massive gap in MRP and cost to retailers

The Supreme Court focused on the unusually wide difference between a medicine’s maximum retail price, or MRP, and the price retailers pay to obtain it. A large gap can create substantial room for markups before the medicine reaches patients. The bench wanted to know why the pricing system appeared to benefit pharmaceutical manufacturers more than consumers.

The court’s concern was not simply that prices differ at different supply-chain stages. It questioned whether the difference was excessive and whether the government was adequately monitoring it. The bench told the Centre that the practice was happening “under the government's own eyes” and asked, “Should it be allowed to run amok?”

The hearing placed responsibility for oversight at the centre of the dispute. The bench described the National Pharmaceutical Pricing Authority as appearing “totally defunct.” The court reserved its order, so the article does not report a final ruling or a new nationwide pricing rule.

MRP means maximum retail price. It is the highest price printed on a medicine pack for sale to consumers, subject to applicable rules. The retailer’s purchase price is the amount the retailer pays a distributor, wholesaler, or supplier to acquire that medicine. It is normally lower than the MRP.

Trade margin is the amount left between a medicine’s purchase price and its selling price. For example, if a retailer buys a medicine for ₹70 and sells it at an MRP of ₹100, the gross difference is ₹30, or 30% of MRP. The exact commercial calculation can vary depending on the pricing rule and supply-chain stage.

The Supreme Court questioned this gap because a very large difference can raise patient costs without clearly reflecting production or distribution expenses. The article does not provide a particular medicine’s prices, but it says the difference between MRP and retailer purchase prices was significant.

The proposed measure would limit the trade margin on anti-cancer medicines to 30% of their MRP. The Centre told the Supreme Court that this important decision was expected to produce annual savings of approximately ₹2,500 crore for patients. The figure indicates the estimated combined reduction in patient spending across affected medicines.

The mechanism is straightforward. If the gap between a medicine’s purchase price and its permitted selling price is restricted, hospitals, retailers, or other sellers have less room to add large markups. The saving would therefore come from lower trade margins rather than from a single cash payment to patients. The article does not give an average saving per patient.

The proposal’s broader significance is that the court questioned why similar margin limits could not apply to other medicines. On October 12, it said the Centre’s response was “hardly anything to be happy about.” The article does not confirm final implementation beyond the Centre’s stated decision.

The National Pharmaceutical Pricing Authority, or NPPA, is the government body responsible for regulating medicine prices in India. The article identifies it as the organisation that should oversee drug pricing. Its role matters because medicines can pass through manufacturers, distributors, retailers, and hospitals before reaching patients.

Under India’s price-control framework, the NPPA generally sets or enforces permitted prices for medicines covered by government rules. It can monitor market prices, check whether sellers exceed approved limits, calculate or revise controlled prices, and pursue recovery of overcharged amounts under applicable law. These powers explain why the court focused on the authority’s effectiveness.

During the hearing, the Supreme Court described the NPPA as appearing to be a “totally defunct” organisation. That criticism suggests concern about enforcement, not merely the existence of pricing rules. The article does not provide a detailed list of NPPA actions in this case, and the court reserved its order.

The Centre’s position was that “the entire ecosystem is not to be controlled.” Pharmaceutical pricing involves several linked stages, from manufacturing and distribution to retail and hospital sales. Controlling every price or margin could make the system less flexible, especially when costs and supply conditions differ across medicines.

Additional Solicitor General Aishwarya Bhati told the court that medicine prices in India were among the lowest in the world. She argued that policy must balance affordability with the availability of medicines and the broader interests of the pharmaceutical industry. In practice, that means trying to prevent excessive patient charges without discouraging production or disrupting supply.

The Supreme Court was unconvinced that the existing oversight was adequate. It questioned why the system appeared to favour manufacturers and criticised the NPPA’s apparent ineffectiveness. The court’s challenge is therefore about where to draw the line: enough control to protect patients, but not so much that availability and industry capacity suffer.

When a medicine receives a very high markup, the patient pays much more than the underlying purchase or supply-chain cost. That matters most for essential, life-saving, or anti-cancer medicines, where patients may have little choice about whether to buy them. Higher prices can increase financial pressure and make necessary treatment less accessible.

The article gives the example of steep markups on cancer drugs by hospitals, for which the Supreme Court had earlier criticised the Centre. It also describes the proposed 30% trade-margin cap on anti-cancer medicines. The intended mechanism is to limit the amount that sellers can add above the relevant purchase or controlled price.

The Centre estimated that the anti-cancer measure could save patients approximately ₹2,500 crore annually. The court also questioned why other medicines could not receive similar protection. The article does not quantify delayed treatments, health outcomes, or individual patient savings, so those effects cannot be measured from the supplied text.

Medicine-price regulation generally uses different tools for different medicines. Government rules can place ceilings on the prices of covered drugs, while regulators monitor whether companies and sellers stay within those limits. Trade-margin limits address the amount added between purchase and sale. Together, these tools aim to protect patients from excessive charges.

Competition is another mechanism. When several manufacturers and sellers offer comparable medicines, buyers may have more alternatives and prices may face downward pressure. Competition is weaker when a medicine is essential, specialised, or supplied by few companies. That is why regulation can remain important even where market competition exists.

The article centres on whether the current system is sufficient. The Centre said the entire ecosystem should not be controlled, while the Supreme Court questioned the large gap between MRP and retailer purchase prices. It also criticised the NPPA’s apparent condition. The hearing ended with the order reserved, so the article gives no final reform or enforcement outcome.